PARP1 and neoplasm: The preclinical validation of this concept stems from sequential investigations: initial work first demonstrated in tumor cell lines that the “switch” to PARP1-EJ repair constitutes the key mechanism underlying olaparib-mediated radiosensitization, a process independent of homologous recombination status (64).